ASCO 2018: Choices for front-line NSCLC
With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…
With permutations of potential front-line treatments for non-small cell lung cancer (NSCLC) seemingly endless, one thing seems certain…
Hot topics in lung cancer – interviews from ASCO 2018.
June 2018 saw the launch of our first edition of LungCancer.Med, a new congress news e-journal containing interviews with speakers and delegates as well as articles on the latest hot… read more.
In addition to clinical segmentation of MM patients as young or elderly and fit or frail, genetic factors convey important prognostic information and should be taken into account… read more.
Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.
In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.
BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients ……
The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.